Literature DB >> 16284440

Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study.

Yusuke Taniyama1, Takashi Suzuki, Yoshiki Mikami, Takuya Moriya, Susumu Satomi, Hironobu Sasano.   

Abstract

Somatostatin is well known to inhibit the hormone secretion of various peptides. This action has been considered to be generally mediated via six different specific somatostatin receptors (sstr), sstr1, sstr2A, sstr2B, sstr3, sstr4, and sstr5. It then becomes very important to demonstrate the localization of these sstr subtypes in order to elucidate the possible biological and/or clinical significance of somatostatin actions. These sstr subtypes have been demonstrated to be expressed throughout the human body, including the central nervous system, gastrointestinal tract, pancreas, kidney, and other organs, but its details, especially its systemic distribution and localization in tissue compartments, have yet to be examined thoroughly in human. Therefore, in this study, we examined the systemic localization of all six somatostatin receptors in normal human organs using immunohistochemistry with recently developed specific antibodies against these receptor subtypes. In all of the human tissues examined, various sstr subtypes were detected not only in parenchymal cells but also in various stromal cells such as lymphocytes, fibroblasts, and endothelial cells. Among human tissues in which the presence of sstr has not been previously reported, the parotid gland demonstrated immunoreactivity for sstr2B and sstr5, bronchial gland for sstr1, 2B, 3, 4, 5, parathyroid gland for sstr1, 3, 4, and duodenum for all subtypes immunoreactivity. The great majority of other organs examined demonstrated results consistent with those of previously reported biochemical studies. In pancreatic islet cells, only sstr2A was positive in all the cases but other sstr subtypes were associated with marked intraislet heterogeneity in their distribution. In stomach, all subtypes of receptor were detected in various cell types of the mucosa, but none in ECL cells of fundic gland. These findings demonstrated the broad systemic actions of somatostatin in non-endocrine cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284440     DOI: 10.1507/endocrj.52.605

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  41 in total

1.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

2.  99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

Authors:  Lilian Yuri Itaya Yamaga; Guilherme Campos Carvalho Neto; Marcelo Livorsi da Cunha; Akemi Osawa; Julio Cesar Silveira Oliveira; Ricardo Quartim Fonseca; Solange Amorim Nogueira; Jairo Wagner; Marcelo Gusmão Funari
Journal:  Radiol Med       Date:  2015-11-12       Impact factor: 3.469

Review 3.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

4.  Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Vikas Prasad; Harshad Kulkarni; Sven-Petter Haugvik; Merten Hommann; Richard Paul Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-31       Impact factor: 9.236

5.  Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study.

Authors:  Evanthia Diakatou; Gregory Kaltsas; Michail Tzivras; George Kanakis; Eugenia Papaliodi; George Kontogeorgos
Journal:  Endocr Pathol       Date:  2011-03       Impact factor: 3.943

6.  Imaging of gastroenteropancreatic neuroendocrine tumors.

Authors:  Eik Hock Tan; Cher Heng Tan
Journal:  World J Clin Oncol       Date:  2011-01-10

Review 7.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

8.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice.

Authors:  Zsuzsanna Helyes; Erika Pintér; Katalin Sándor; Krisztián Elekes; Agnes Bánvölgyi; Dániel Keszthelyi; Eva Szoke; Dániel M Tóth; Zoltán Sándor; László Kereskai; Gábor Pozsgai; Jeremy P Allen; Piers C Emson; Adrienn Markovics; János Szolcsányi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

10.  Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Authors:  Jaap J M Teunissen; Eric P Krenning; Frank H de Jong; Yolanda B de Rijke; Richard A Feelders; Maarten O van Aken; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.